Exelixis
- Country
- 🇺🇸United States
- Ownership
- Public
- Established
- 1994-01-01
- Employees
- 1.3K
- Market Cap
- $7.3B
- Website
- http://www.exelixis.com
- Introduction
Exelixis, Inc. operates as an oncology company, which focuses on discovering, developing, and commercialization of new medicines for difficult-to-treat cancers. Its products include cabometyx, cometriq, and cotellic. The company was founded by Stelios Papadopoulos on November 15, 1994, and is headquartered in Alameda, CA.
Clinical Trials
155
Trial Phases
5 Phases
Drug Approvals
2
Clinical Trials
Distribution across different clinical trial phases (137 trials with phase data)• Click on a phase to view related trials
A Study of XB371 Administered in Participants With Locally Advanced or Metastatic Solid Tumors
- First Posted Date
- 2025-08-14
- Last Posted Date
- 2025-08-28
- Lead Sponsor
- Exelixis
- Target Recruit Count
- 150
- Registration Number
- NCT07123103
- Locations
- 🇺🇸
Exelixis Clinical Site #2, Huntersville, North Carolina, United States
🇺🇸Exelixis Clinical Site #1, San Antonio, Texas, United States
Pharmacokinetics (PK) and Safety of Zanzalintinib in Participants With Moderate Hepatic Impairment (HI)
- Conditions
- Hepatic ImpairmentModerate Hepatic Impairment
- Interventions
- First Posted Date
- 2025-05-08
- Last Posted Date
- 2025-06-22
- Lead Sponsor
- Exelixis
- Target Recruit Count
- 20
- Registration Number
- NCT06962332
- Locations
- 🇺🇸
Exelixis Clinical Site #1, Orlando, Florida, United States
🇺🇸Exelixis Clinical Site #2, San Antonio, Texas, United States
A Study of XB628 in Participants With Recurrent Advanced or Metastatic Solid Tumors
- Conditions
- Solid TumorMetastatic Solid TumorAdvanced Solid TumorImmune Sensitive Tumor
- Interventions
- First Posted Date
- 2025-04-30
- Last Posted Date
- 2025-09-08
- Lead Sponsor
- Exelixis
- Target Recruit Count
- 75
- Registration Number
- NCT06952010
- Locations
- 🇺🇸
Exelixis Site #4, New Haven, Connecticut, United States
🇺🇸Exelixis Clinical Site #1, Hickory, North Carolina, United States
🇺🇸Exelixis Clinical Site #3, Nashville, Tennessee, United States
Zanzalintinib Versus Everolimus in Participants With Locally Advanced or Metastatic Neuroendocrine Tumors
- Conditions
- Pancreatic Neuroendocrine Tumor (pNET)Extra-Pancreatic Neuroendocrine Tumor (epNET)
- Interventions
- First Posted Date
- 2025-04-24
- Last Posted Date
- 2025-09-26
- Lead Sponsor
- Exelixis
- Target Recruit Count
- 440
- Registration Number
- NCT06943755
- Locations
- 🇺🇸
Exelixis Clinical Site #9, Lexington, Kentucky, United States
🇺🇸Exelixis Clinical Site #8, Boston, Massachusetts, United States
🇺🇸Exelixis Clinical Site #1, Grand Rapids, Michigan, United States
A Dose-escalation, Dose-finding, and Expansion Study of XL495 in Participants With Locally Advanced or Metastatic Solid Tumors
- Conditions
- Solid CancersSolid Tumor CancerSolid Tumor MalignancyUrothelial Cancer (Urinary Bladder, Ureters, or Renal Pelvis Cancer)Metastatic Solid TumorLocally Advanced Solid TumorUrothelial Cancer of Renal Pelvis
- Interventions
- Drug: ADC cytotoxic agents
- First Posted Date
- 2024-10-08
- Last Posted Date
- 2025-06-25
- Lead Sponsor
- Exelixis
- Target Recruit Count
- 9
- Registration Number
- NCT06630247
- Locations
- 🇺🇸
Exelixis Clinical Site #4, Denver, Colorado, United States
🇺🇸Exelixis Clinical Site #9, New Haven, Connecticut, United States
🇺🇸Exelixis Clinical Site #8, Washington, District of Columbia, United States
- Prev
- 1
- 2
- 3
- 4
- 5
- 11
- Next
News
Ryvu Therapeutics Partners with BioNTech to Accelerate Cancer Immunotherapy Trials in Poland
Ryvu Therapeutics has entered a strategic agreement with BioNTech to support clinical trial site activation and patient recruitment for multiple investigational cancer immunotherapies in Poland.
Exelixis Promotes Dana Aftab to Lead Consolidated R&D Operations Amid Strategic Restructuring
Exelixis has promoted Dana T. Aftab, Ph.D., to Executive Vice President of Research and Development, consolidating discovery, translational research, and late-stage development under unified leadership.
Exelixis Closes Pennsylvania Facility, Cuts 130 Jobs in Strategic Consolidation
Exelixis will close its King of Prussia, Pennsylvania facility and lay off 130 employees, representing an 11% workforce reduction as the company consolidates operations in California.
Zentalis Pharmaceuticals Appoints James B. Bucher as Chief Legal Officer to Support Azenosertib's Advancement
Zentalis Pharmaceuticals has appointed James B. Bucher as Chief Legal Officer and Corporate Secretary, effective September 18, 2025, bringing over 30 years of life sciences legal experience.
BioNTech's BNT113 mRNA Cancer Vaccine Advances in Phase 2 Trial for HPV+ Head and Neck Cancer
BioNTech's BNT113, an mRNA cancer vaccine targeting HPV16+ oncoproteins E6 and E7, is being evaluated in the Phase 2 AHEAD-MERIT trial combined with pembrolizumab versus pembrolizumab alone for unresectable recurrent or metastatic HPV+ head and neck squamous cell carcinoma.
Major Pharmaceutical Companies Face Surge in Generic Drug Patent Challenges in Early 2025
Major pharmaceutical companies including AstraZeneca, Novartis, and Astellas are defending patents for blockbuster drugs like Lynparza, Entresto, and Xtandi against generic manufacturers in early 2025.
Bristol-Myers Squibb, Exelixis, and Novartis Advance Pan-Tumor Rollover Study for Long-Term Nivolumab Safety Assessment
Bristol-Myers Squibb, Exelixis, and Novartis are collaborating on the Pan-Tumor Rollover Study to evaluate the long-term safety of nivolumab monotherapy and its combinations across various tumor types.
Comprehensive Pipeline Analysis Reveals 200+ Investigational Drugs for Metastatic Hormone Refractory Prostate Cancer
A new comprehensive report analyzes over 200 pipeline drugs from 180+ companies targeting metastatic hormone refractory prostate cancer, highlighting the extensive research efforts in this challenging therapeutic area.
Dual-Payload ADCs Enter Clinical Testing as Innovent and Chengdu Kanghong Pioneer Next-Generation Cancer Therapeutics
Innovent's IBI3020, a dual-payload ADC targeting CEACAM5, has begun first-in-human trials for solid tumors, marking a significant milestone in next-generation cancer therapeutics.
Exelixis Reports Promising Results for Zanzalintinib Combination in Advanced Kidney Cancer
Zanzalintinib combined with nivolumab demonstrated a 63% objective response rate and 90% disease control rate in previously untreated advanced clear cell renal cell carcinoma patients.